Recall Roundup for Week of May 12, 2025: Ice Cream, Coolers, Eye Drops & More Pulled from Shelves
There were several major recalls involving wildly popular products and big-name companies over the last 7-10 days, so check your cupboards and pantries for any recalled items you may have purchased in recent months.
Some of the items pulled from shelves include ice cream contaminated with plastic, coolers potentially amputating fingertips, eyecare products pulled over sterility issues, and ready-to-eat food items linked to Listeria concerns and undeclared allergens.
Here's what to throw out or return for the week of May 12, 2025:
Thousands of gallons of popular ice cream products were pulled from shelves due to a possible contamination of hard plastics in the desserts.
The voluntary recall was made by Wells Enterprises, maker of popular ice cream brands like Blue Bunny, Halo Top, Bomb Pop and Blue Ribbon Classics.
22 varieties of ice cream products were affected by the recall and were distributed to over 100 facilities across the U.S. including restaurants, cafeterias and food service companies.
Check out a complete list of flavors and brands that were recalled here.
Igloo expanded its recall of 90-quart rolling coolers "due to fingertip amputation and crushing hazards," according to a notice on the U.S. Consumer Product Safety Commission.
The coolers were recalled due to safety issues with the tow handle of the cooler, which can "pinch consumers' fingertips against the cooler, posing fingertip amputation and crushing hazards," the notice states.
More than one million coolers were previously recalled in February, and an additional 130,000 were pulled after the recall was expanded on May 8, 2025
The recall was expanded due to "78 more reports of fingertip injuries, including 26 resulting in fingertip amputations, bone fractures or lacerations," according to USA Today.
Fresh & Ready Foods voluntarily recalled 86 different ready-made products including sandwiches, snacks, and pastas across four states due to potential contamination of listeria.
At least 10 people across California and Nevada have been hospitalized with symptoms related to the listeria outbreak, which has been linked to ready-to-eat food products.
After a routine inspection, the FDA identified Fresh & Ready Foods as the source of a Listeria outbreak from last year.
For the full list of recalled products, go to the FDA's website.
More than 75,000 cases over-the-counter eye care products including artificial tears and other ophthalmic solutions distributed by AvKARE were recalled over a potential sterility issue.
The voluntary recall was issued after a U.S. Food and Drug Administration (FDA) audit uncovered a manufacturing deviation that may pose a health risk to consumers, although the health risk was not specified in the report.
On May 6, the FDA gave the recall the second-highest risk level.
You can find specific lot codes and expiration dates on the AvKare news release, as well as a full list of the recalled items.
Ford announced a massive recall of 274,00 Expedition and Lincoln-branded Navigator SUVs due to the potential loss of brake function while driving.
Documents published by the National Highway Traffic Safety Administration state that the front brake lines in these cars 'may be in contact' with their engine air cleaner outlet pipe due to a potential installation defect.
"Front brake lines in the affected vehicles may be in contact with the engine air cleaner outlet pipe," the recall states. "This can result in a brake line leak."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval
Verastem Oncology VSTM shares rallied 22.2% in a month, primarily driven by the FDA approval of the company's novel combination regimen of avutometinib plus defactinib in early May for treating KRAS mutant recurrent low-grade serous ovarian cancer (LGSOC), a rare and distinct type of ovarian cancer. The FDA's decision came well in advance of the originally expected date of June 30, 2025. The approval was granted under the FDA's accelerated approval pathway and is commercialized in the U.S. market as an oral combination co-pack with the two prescription products, known as 'Avmapki Fakzynja Co-Pack.' Following the FDA approval, Avmapki Fakzynja Co-Pack is the first and only FDA-approved treatment for the LGSOC indication. Per Verastem Oncology, the combo offers a much-needed treatment option for patients and sets a new standard of care for women with recurrent LGSOC with a KRAS mutation. Full approval of the product for this use depends on the detailed evidence of clinical benefit in the follow-up phase III RAMP 301 confirmatory study, which will evaluate the combination in women with and without a KRAS mutation. Year to date, Verastem Oncology stock has surged 64.8% against the industry's 5.8% decline. Image Source: Zacks Investment Research Please note that the FDA's decision was based on the results from VSTM's phase II RAMP 201 study, which evaluated the combination of Avmapki and Fakzynja in adult patients with measurable KRAS-mutated recurrent LGSOC. Per the data readout, a 44% overall response rate was observed in patients treated with the combo therapy, with an acceptable safety profile. Additionally, the median duration of response ranged from 3.3 to 31.1 months in the KRAS mutant population. The Avmapki/Fakzynja combo enjoys the FDA's Breakthrough Therapy designation for the treatment of patients with recurrent LGSOC after one or more prior lines of therapy, including platinum-based chemotherapy, in the United States. Avutometinib alone or in combination with defactinib also enjoys the FDA's Orphan Drug designation for the same indication. Verastem Oncology is also looking to expand the label of its approved avutometinib/defactinib combo therapy beyond LGSOC. Last week, VSTM reported positive updated safety and efficacy results from the phase I/II RAMP 205 study evaluating avutometinib plus defactinib in combination with chemotherapy (gemcitabine and Nab-paclitaxel) for the first-line treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) patients. This has also likely contributed to the stock price rally in the past month. The RAMP 205 study is evaluating 60 patients in five cohorts (12 per cohort) who are receiving one of five dose regimens of avutometinib/defactinib combo with chemotherapy for frontline metastatic PDAC. As of April 25, 2025, patients in the dose level 1 cohort achieved an overall response rate of 83% (eight confirmed and two unconfirmed who remain on treatment). Based on this encouraging outcome, Verastem Oncology selected dose level 1 as the recommended phase II dose. Additionally, it was found that the dose level 1 showed the best response, and overall, 92% of patients across all dose levels achieved tumor shrinkage. The safety profile of the avutometinib/defactinib combo was acceptable across all the treatment cohorts and no new safety signals were identified. Verastem Oncology is currently gearing up to initiate a registrational phase III front-line metastatic PDAC study in 2026. Apart from these indications, the company is simultaneously evaluating avutometinib and defactinib in combination with a KRAS G12C inhibitor, sotorasib, for treating non-small cell lung cancer in a separate mid-stage study. Verastem, Inc. price-consensus-chart | Verastem, Inc. Quote Verastem Oncology currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the biotech sector are Bayer BAYRY, Lexicon Pharmaceuticals LXRX and Amarin AMRN, each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. In the past 60 days, estimates for Bayer's earnings per share have increased from $1.19 to $1.25 for 2025. During the same time, earnings per share have increased from $1.28 to $1.31 for 2026. Year to date, shares of Bayer have gained 45.3%. BAYRY's earnings beat estimates in one of the trailing four quarters, matched twice and missed on the remaining occasion, the average negative surprise being 13.91%. In the past 60 days, estimates for Lexicon's loss per share have narrowed from 37 cents to 32 cents for 2025. During the same time, loss per share estimates for 2026 have narrowed from 35 cents to 31 cents. Year to date, shares of LXRX have lost 6.6%. LXRX's earnings beat estimates in three of the trailing four quarters and missed the same on the remaining occasion, delivering an average surprise of 11.97%. In the past 60 days, estimates for Amarin's loss per share have narrowed from $5.33 to $3.48 for 2025. During the same time, loss per share estimates for 2026 have narrowed from $4.13 to $2.67. Year to date, shares of AMRN have gained 17.1%. AMRN's earnings beat estimates in two of the trailing four quarters, matched once and missed the same on the remaining occasion, delivering an average surprise of 29.11%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report Lexicon Pharmaceuticals, Inc. (LXRX) : Free Stock Analysis Report Amarin Corporation PLC (AMRN) : Free Stock Analysis Report Verastem, Inc. (VSTM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
FDA Expands Cucumber Recall Amid Salmonella Outbreak
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."Cucumber recall expands amid Salmonella outbreak. Bedner Growers Inc. cucumbers included in products by various brands are now being recalled. Below, find a list of impacted products. Last month's cucumber recall is expanding amid a Salmonella outbreak. The U.S. Food and Drug Administration (FDA) recently updated the products associated with the original Bedner Growers, Inc. recall to include products that either use the recalled cucumbers in their ingredients or feature the cucumbers under new packaging. According to updated statements shared by the FDA on May 28, 2025, and June 4, 2025, the initial Bedner Growers Inc. recall now also includes the following items (full UPC codes and best-by dates can be found in the initial recall statements): Mai sushi—various sushi rolls and boxes Kings, Isabelle's Kitchen Inc., Maple Avenue Foods—prepackaged salads Supreme Produce—fresh-cut salad and vegetable trays Snowfruit & Snowfox—fresh-cut cucumbers and sushi East Coast Fresh, TOPS, Wellsley Farms, Weis, Ahold, Jack and Olive, Created Fresh, Spring and Sprout—Salads, salsas, and other products that include the salsa made with Bedner Growers cucumbers PennRose Farms—whole cucumbers Marketside—fresh-cut cucumbers Read to Eat and Star Market—Greek salad Ukrop's—marinated cucumber salad Big Y Foods—made-to-order sandwiches, wraps, and paninis TGD Cuts—salsa, hot 6/12 oz. TGD Cuts—salsa, mild 6/12 oz. TGD Cuts—salsa, mild 5lb. TGD Cuts—salsa, mild 5lb. TGD Cuts—cucumber sliced/grape tomato 50/2oz. TGD Cuts—cucumber sliced unpeeled 5lb. TGD Cuts—cucumber sliced unpeeled 50/2oz. TGD Cuts—cucumber spears 50/2oz. These products were sold under various brand names, including Jenny's Classic, Mia, Supreme Produce, and more, at big chain stores like Walmart and Target (see here for a comprehensive list of impacted products), as well as smaller chains, nationwide. According to the original recall statement, the cucumbers from sampling tested positive for Salmonella Montevido. Additional samples taken at the same time and location also came back positive for other strains that the FDA believes are unrelated to the current outbreak that, as of press time, have sickened 45 and sent 16 to the hospital. According to the Mayo Clinic, symptoms of a salmonella infection—also known as salmonellosis, and involves the intestinal tract—may range from mild to severe. While some people who develop salmonellosis may have no symptoms at all, others may experience more moderate symptoms, which may include diarrhea, stomach cramps, and fever. Those with more severe symptoms may experience dehydration as a result of the infection, which can require medical attention. While rare, some can experience life-threatening complications, which typically occur when the Salmonella infection moves beyond the intestines and into other parts of the body. Most people do not need to seek medical attention for a Salmonella infection, however, there are times when you should call your healthcare provider. For example, if you experience symptoms that last longer than just a few days, develop a fever, or begin to notice signs of dehydration, you should reach out to your medical provider at once. The FDA urges consumers not to eat any product that they suspect is a part of the recall. Instead, safely dispose of it or return it to the point of purchase. If you have questions about this recall and your personal medical risk, you should contact your doctor for more information. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
3 hours ago
- Yahoo
For The Best Mayo-Free Tuna Salad Reach For This Creamy Ingredient Instead
Americans have long considered tuna salad a healthy meal, thanks in part to tuna's important nutrients like protein and calcium. Canned tuna also means it's easy to make. But tuna salad's reputation as a simple diet food can be undermined by one common ingredient: mayonnaise. Whether for health reasons or personal preference, Greek yogurt makes a great substitute in tuna salad. Greek yogurt is significantly lower in sodium, calories, fat, and cholesterol than mayonnaise, which contains at least 65% vegetable oil per FDA regulations. Greek yogurt's similarly creamy texture will help hold the salad together, and although it doesn't taste like mayo, the tart tanginess of Greek yogurt is also great for letting tuna and other ingredients shine. Greek yogurt is also a particularly nutritious addition. It contains vitamin B12, which boosts nervous system function, as well as selenium and zinc, two elements that are important for a healthy immune system. It's also notably high in protein, further boosting the already protein-rich nature of this food. Read more: 14 Condiments That Don't Need To Be Refrigerated It's possible to freeze tuna salad for up to two months if you use full-fat Greek yogurt. Mayonnaise and low-fat Greek yogurt are both prone to separating when frozen, which can ruin the texture. Full-fat is thicker, which helps maintain creaminess when thawed. And though it's high in fat, they are healthy fats associated with a lower risk of diabetes and higher HDL cholesterol (the good kind). A tip for a better-tasting tuna salad is to drain canned tuna first, whether it is eaten fresh or frozen. Removing excess oil or brine from the tuna will help the Greek yogurt stick better, creating improved consistency. When freezing the tuna salad, that excess liquid could lead to the formation of ice crystals and freezer burn, so it's best to leave it out. Like full-fat Greek yogurt, many unexpected tuna salad ingredient additions freeze well when stored correctly in an airtight container, including chickpeas and jalapeños. But other potential components may soften after freezing, including conventional ones like celery and tomatoes, as well as unconventional choices like kimchi and apples. Hungry for more? Sign up for the free Daily Meal newsletter for delicious recipes, cooking tips, kitchen hacks, and more, delivered straight to your inbox. Read the original article on The Daily Meal.
